← Back to patent-cliff list
伊班膦酸钠
Tier C — Watch / tradeIbandronate Sodium Hydrate
基因泰克
Originator
1996
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Bone resorption factor、FDPS
Brand：Bondronat、Bondenza、Bonviva (former Brand Name)、Destara、Bonviva、Boniva/Bonviva、Boniva
Indications (approved)：骨质疏松症、绝经期后骨质疏松、高钙血症、骨损伤、乳腺癌、转移癌
Regional status
US
撤市
EU
批准上市
1996-06-25
China
批准上市
2001-01-01
Japan
批准上市
2013-06-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ibandronate Sodium Hydrate?
Approved indications include: 骨质疏松症, 绝经期后骨质疏松, 高钙血症, 骨损伤, 乳腺癌, 转移癌.
When does the Ibandronate Sodium Hydrate patent expire?
No public expiry year is available for Ibandronate Sodium Hydrate yet; this page updates once verified.
How do I get a quote for Ibandronate Sodium Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25